# Rezolute (RZLT) — News

RZLT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rzlt/news

## Recent headlines

- [Rezolute - Primary endpoint is 50% reduction in glucose infusion rate within 8 weeks](https://www.ainvest.com/news/rezolute-primary-endpoint-50-reduction-glucose-infusion-rate-8-weeks-2610) — AInvest Wire, Oct 14, 2026
  Rezolute, Inc. (Nasdaq: RZLT) recently reported outcomes from its Phase 3 sunRIZE trial of ersodetug for the treatment of congenital hyperinsulinism (HI). The study aimed to evaluate the safety and efficacy of the therapy, with a primary endpoint of a 50% reduction in glucose infusion rate within 8…
- [Rezolute announces completion of enrollment in phase 3 uplift study of Ersodetug in tumor hyperinsulinism](https://www.ainvest.com/news/rezolute-announces-completion-enrollment-phase-3-uplift-study-ersodetug-tumor-hyperinsulinism-2610) — AInvest Wire, Oct 14, 2026
  Rezolute, Inc. (Nasdaq: RZLT) announced that it has completed enrollment in its Phase 3 upLIFT study of Ersodetug for the treatment of tumor hyperinsulinism (HI) . The study, which is evaluating the safety and efficacy of Ersodetug in patients with hypoglycemia caused by insulinoma or non-islet…
- [Rezolute - On track to report phase 3 uplift study topline results in tumor HI this quarter](https://www.ainvest.com/news/rezolute-track-report-phase-3-uplift-study-topline-results-tumor-quarter-2610) — AInvest Wire, Oct 5, 2026
- [Rezolute announces FDA recommendation to hold a pre-BlA meeting](https://www.ainvest.com/news/rezolute-announces-fda-recommendation-hold-pre-bla-meeting-2610) — AInvest Wire, Oct 5, 2026
- [Rezolute announces FDA recommendation to hold a pre-BlA meeting as a precursor to submitting a biologics license application (BLA) for congenital hyperinsulinism](https://www.ainvest.com/news/rezolute-announces-fda-recommendation-hold-pre-bla-meeting-precursor-submitting-biologics-license-application-bla-congenital-hyperinsulinism-2610) — AInvest Wire, Oct 5, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).